Skip to main content
. 2021 Mar 19;39(18):1959–1970. doi: 10.1200/JCO.20.03175

TABLE 2.

Summary of Adverse Events in Patients Receiving Glofitamab at Any Dose and at the RP2D (Safety-Evaluable Patients)

graphic file with name jco-39-1959-g002.jpg